General Information of Drug (ID: DMQOJY2)

Drug Name
OPC 4392 Drug Info
Synonyms OPC-4392
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
163839
CAS Number
CAS 111073-34-8
TTD Drug ID
DMQOJY2

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug(s) Targeting 5-HT 6 receptor (HTR6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
LU AE58054 DMWGRQD Schizophrenia 6A20 Phase 3 [3]
SB-742457 DM6L4ZT Alzheimer disease 8A20 Phase 3 [4]
AVN 211 DMVB4OS Schizophrenia 6A20 Phase 2/3 [5]
SYN120 DMDF7XB Parkinson disease 8A00.0 Phase 2 [6]
AVN 101 DMJFLBC Alzheimer disease 8A20 Phase 2 [5]
SYN-120 DMPW0UL Alzheimer disease 8A20 Phase 2 [7]
PF-05212377 DMPVQYR Alzheimer disease 8A20 Phase 2 [8]
AVN 322 DMK2LGM Cognitive impairment 6D71 Phase 2 [4]
SAM-531 DMHVJZ6 Alzheimer disease 8A20 Phase 2 [9]
SUVN-502 DMQD753 Alzheimer disease 8A20 Phase 2 [10]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 7 receptor (HTR7)
Drug Name Drug ID Indication ICD 11 Highest Status REF
RP5063 DMKUE8O Schizophrenia 6A20 Phase 2 [11]
JNJ-18038683 DMV1T59 Major depressive disorder 6A70.3 Phase 2 [12]
AVN-101 DMOGFNI Cognitive impairment 6D71 Phase 2 [13]
ATI-9242 DM6GKMU Schizophrenia 6A20 Phase 1 [14]
PMID30124346-Compound-34TABLE4 DM2G3VE Attention deficit hyperactivity disorder 6A05.Z Patented [15]
PMID30124346-Compound-13TABLE4 DMHTJVA Attention deficit hyperactivity disorder 6A05.Z Patented [15]
Carbamide derivative 2 DMW5GI3 N. A. N. A. Patented [16]
4-oxadiazole derivative 1 DMWFHKR N. A. N. A. Patented [16]
SB-269970 DM8WTGA Sleep-wake disorder 7A00-7B2Z Terminated [17]
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G Discovery agent N.A. Investigative [18]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 6 receptor (HTR6) TTJS8PY 5HT6R_HUMAN Agonist [2]
5-HT 7 receptor (HTR7) TTO9X1H 5HT7R_HUMAN Agonist [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 268).
2 Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology. 1999 Jun;20(6):612-27.
3 Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. Int J Neuropsychopharmacol. 2010 Sep;13(8):1021-33.
4 5-HT6 receptors and Alzheimer's disease. Alzheimers Res Ther. 2013; 5(2): 15.
5 Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea. Curr Opin Investig Drugs. 2010 January; 11(1): 80-91.
6 Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. Nat Rev Drug Discov. 2018 Nov;17(11):804-822.
7 The Serotonin-6 Receptor as a Novel Therapeutic Target. Exp Neurobiol. 2011 December; 20(4): 159-168.
8 PF-05212377 Alzheimer's Disease (Phase 2). Pfizer.
9 Activation of 5-HT6 receptors modulates sleep-wake activity and hippocampal theta oscillation. ACS Chem Neurosci. 2013 Jan 16;4(1):191-9.
10 Novel and Potent 5-Piperazinyl Methyl-N1-aryl Sulfonyl Indole Derivatives as 5-HT6 Receptor Ligands. ACS Med Chem Lett. 2010 October 14; 1(7): 340-344.
11 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
12 Selective pharmacological blockade of the 5-HT7 receptor attenuates light and 8-OH-DPAT induced phase shifts of mouse circadian wheel running activity. Front Behav Neurosci. 2015 Jan 15;8:453.
13 AVN-101: A Multi-Target Drug Candidate for the Treatment of CNS Disorders. J Alzheimers Dis. 2016 May 25;53(2):583-620.
14 Pharmacological characteristics of ATI-9242, a Novel Atypical Antipsychotic. FASEB J, April, 2010, 24(Meeting Abstract Supplement),773.12.
15 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
16 Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58.
17 [(3)H]-SB-269970--A selective antagonist radioligand for 5-HT(7) receptors. Br J Pharmacol. 2000 May;130(2):409-17.
18 Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.